top of page

CADTH RDR RFP Supplemental Material


1.     Public Health Agency of Canada, Statistics Canada, Canadian Cancer Society & provincial/territorial cancer registries. Release notice - Canadian cancer statistics 2019. Health Promot. Chronic Dis. Prev. Can. 39, 255 (2019).

2.     Ramjeesingh, R. et al. A practical guide for the systemic treatment of biliary tract cancer in Canada. Curr. Oncol. 30, 7132–7150 (2023).

3.     Benson, A. B. et al. NCCN guidelines® insights: Biliary Tract Cancers, version 2.2023. J. Natl. Compr. Canc. Netw. 21, 694–704 (2023).

4.     Vogel, A. et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 127–140 (2023).

5.     Shroff RT, Ilyas SI, Javle MM, Valle JW, Azad NS, Borad MJ, Nottke A, Hu J, Stirnadel-Farrant HA, Valerio SJ, Maithel SK. Patient characteristics, treatment patterns, and outcomes in patients with cholangiocarcinoma in the United States. (04-2024).

6.     REDCap.

7.     Marathon of Hope Cancer Centres Network. Home. Marathon of Hope Cancer Centres Network

8.     Precision oncology - better treatment decisions & outcomes. Exactis Innovation | Exactis | The Future of Clinical Cancer Research (2023).

9.     International cholangiocarcinoma patient registry (ICPR).

10.   Nottke, A. et al. Validation and clinical discovery demonstration of breast cancer data from a real-world data extraction platform. JAMIA Open 7, (2024).

11.   Canadian Cancer Society / Société canadienne du cancer. Building a national network for people with biliary tract cancers. Canadian Cancer Society

12.   The Alliance.

13.   Cholangiocarcinoma Foundation – To find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer).

14.   Privacy Management Framework. AICPA

15.   Invitae Corporation. Invitae’s real-world ciitizen data utilized in Praxis Precision Medicines’ PRAX-222 IND filing. PR Newswire (2022).

16.   Government of Canada & Canada, S. Census profile, 2016 Census - Canada [Country] and Canada [Country]. (2017).

17.   Boulanger, A. M. The use of machine translation and AI in medical translation: Pros and cons. Med. Writ. 33, 62–65 (2024).

18.   Khan, S. A. et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61, 1657–1669 (2012).

19.   Pisa, F., Arias, A., Bratton, E., Salas, M. & Sultana, J. Real world data for rare diseases research: The beginner’s guide to registries. Expert Opin. Orphan Drugs 11, 9–15 (2023).

20.   Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).

21.   CADTH. Pemigatinib (Pemazyre) CADTH Reimbursement Recommendation. (2022).

bottom of page